Ann: Dimerix Presents at ASX Small & Mid-Cap Conference, page-27

@ma420
lurk and learn for sure, but be aware that this poster Owl vs Fox is over-optimistic when bigging up this asset. The DMX200 drug did nothing of any note in the covid trials, it's been reported, so how one extrapolates that to pulmonary fibrosis is beyond me. There's never been any evidence put forward that this drug does anything in lung disease of any description.
And as for diabetic kidney disease (DKD), the landscape has completely changed in the last 3-4 years with sglt2 inhibitors, glp1 receptor agonists and finerenone which all have fantastic long term ('hard' outcome) results in DKD and will probably be used in various combinations. So IMO the good ship DKD has sailed and is out of sight for DMX. Owl vs Fox is right that a phase 3 trial in DKD would need 1000s of patients, probably 10s of thousands as it would have to be used on top of these new standard of care drugs- trials of that sort of size are in the $500M-1BN price range. You'd have to be insane to take this DMX drug, which had such underwhelming data in phase 2 , and place a 1BN bet on it in phase 3.